Finch GL - Search Results

1

Key considerations in the preclinical development of biosimilars.

Bui LA, Hurst S, Finch GL, Ingram B, Jacobs IA, Kirchhoff CF, Ng CK, Ryan AM. Bui LA, et al. Among authors: finch gl. Drug Discov Today. 2015 May;20 Suppl 1:3-15. doi: 10.1016/j.drudis.2015.03.011. Epub 2015 Apr 23. Drug Discov Today. 2015. PMID: 25912284 Review.

2

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.

Jacobs I, Petersel D, Shane LG, Ng CK, Kirchhoff C, Finch G, Lula S. Jacobs I, et al. BioDrugs. 2016 Dec;30(6):489-523. doi: 10.1007/s40259-016-0199-9. BioDrugs. 2016. PMID: 27807766 Free PMC article. Review.

3

Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).

Ryan AM, Sokolowski SA, Ng CK, Shirai N, Collinge M, Shen AC, Arrington J, Radi Z, Cummings TR, Ploch SA, Stephenson SA, Tripathi NK, Hurst SI, Finch GL, Leach MW. Ryan AM, et al. Among authors: finch gl. Toxicol Pathol. 2014 Oct;42(7):1069-81. doi: 10.1177/0192623313520351. Epub 2014 Mar 6. Toxicol Pathol. 2014. PMID: 24604381

4

Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).

Hurst S, Ryan AM, Ng CK, McNally JM, Lorello LG, Finch GL, Leach MW, Ploch SA, Fohey JA, Smolarek TA. Hurst S, et al. Among authors: finch gl. BioDrugs. 2014 Oct;28(5):451-9. doi: 10.1007/s40259-014-0103-4. BioDrugs. 2014. PMID: 25001079 Free PMC article.

5

Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.

Derzi M, Shoieb AM, Ripp SL, Finch GL, Lorello LG, O'Neil SP, Radi Z, Syed J, Thompson MS, Leach MW. Derzi M, et al. Among authors: finch gl. Regul Toxicol Pharmacol. 2020 Apr;112:104587. doi: 10.1016/j.yrtph.2020.104587. Epub 2020 Jan 30. Regul Toxicol Pharmacol. 2020. PMID: 32006671 Free article.

6

Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.

Peraza MA, Rule KE, Shiue MHI, Finch GL, Thibault S, Brown PR, Clarke DW, Leach MW. Peraza MA, et al. Among authors: finch gl. Regul Toxicol Pharmacol. 2018 Jun;95:236-243. doi: 10.1016/j.yrtph.2018.03.020. Epub 2018 Mar 21. Regul Toxicol Pharmacol. 2018. PMID: 29574193 Free article.

7

Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".

Finch G, Havel H, Analoui M, Barton RW, Diwan AR, Hennessy M, Reddy V, Sadrieh N, Tamarkin L, Wolfgang M, Yerxa B, Zolnik B, Liu M. Finch G, et al. AAPS J. 2014 Jul;16(4):698-704. doi: 10.1208/s12248-014-9608-5. Epub 2014 May 13. AAPS J. 2014. PMID: 24821054 Free PMC article.

8

Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development.

Campion SN, Bowman CJ, Cappon GD, Harrison A, Finch GL, Hurtt ME. Campion SN, et al. Among authors: finch gl. Birth Defects Res B Dev Reprod Toxicol. 2012 Jun;95(3):250-61. doi: 10.1002/bdrb.21014. Epub 2012 Apr 11. Birth Defects Res B Dev Reprod Toxicol. 2012. PMID: 22495820

9

Two-year carcinogenicity study in rats with a nonnucleoside reverse transcriptase inhibitor.

Nambiar PR, Morton D, Dochterman LW, Houle C, Thomford PJ, Fate G, Bailey SA, Finch GL. Nambiar PR, et al. Among authors: finch gl. Toxicol Pathol. 2015 Apr;43(3):354-65. doi: 10.1177/0192623314544381. Epub 2014 Aug 13. Toxicol Pathol. 2015. PMID: 25122632

10

Effects of lersivirine on canine and rodent thyroid function.

Houle CD, Finch GL, Mauthe RJ, Potter DM, Walisser JA, Gardner IB, DeWit RH. Houle CD, et al. Among authors: finch gl. Toxicol Pathol. 2014 Jul;42(5):897-912. doi: 10.1177/0192623313503516. Epub 2013 Oct 16. Toxicol Pathol. 2014. PMID: 24135463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page